Sanofi, Sanofi en nog eens Sanofi

783 Posts, Pagina: « 1 2 3 4 5 6 ... 12 13 14 15 16 17 18 19 20 21 22 ... 36 37 38 39 40 » | Laatste
Aantal posts per pagina:  20 50 100 | Omlaag ↓
Sir Piet
2
We zijn toch geen kinderen hier. We weten toch allemaal als het niet door fase drie heen is is alles onzeker. Focussen wat wel goed gaat en dat groter maken en uitmelken. Wat sanofi betreft is helemaal niet relevant op dit moment. Misschien moeten we ons afvragen of sanofi het wel kan, het wel aan wil en of crucell met andere programma,s niet te veel concurent wordt. Woensdag weten we meer.
aossa
0
Re: uitspraak Viehbacher betreffende cellen:

Uit het verleden weten we dat Aventis-pasteur verschillende cellenlijnen heeft getest en
1. Voor de menselijke cellijn PER.C6 heeft gekozen.
2. Alleen SA de PER.C6 mag gebruiken voor flu vaccine (cfr. exclusief contract).

Derhalve kan Viehbacher in het openbaar stellen dat
Sanofi-Aventis proefondervindelijk heeft vastgesteld dat massaal produceren van flu-vaccine op cellenlijnen nog niet voor morgen is. Bedoelt dan de concurrentie imo en heeft derhalve de tijd om rustig zijn cellen_flu_vaccine te ontwikkelen zonder grote concurrentiele druk.

JMHO !
aossa
0
quote:

wpw schreef:

Je vergeet solvay

Yep, maar moeten nog een adjuvant toevoegen om geschikt te zijn voor pandemie. Mischien dat Crucell die kan leveren (virosome-model).

PS. Cellenlijn van SA is/was in eerste instantie gericht op mogelijke pandemie vogelgriep H5N1. Mogelijk dat de flexibiliteit van hun vaccine-model wat minder is dan verwacht.
B_B
3
Sanofi sets up biotech plant, seeks partnershipsReuters, Tuesday May 5 2009 * To convert French plant to new biotech centre
* Biotechs invited to co-operate at 200 million euro plant

VITRY-SUR-SEINE, France, May 5 (Reuters) - Sanofi-Aventis announced a 200 million euro ($265 million) plan to convert a factory to biotechnology, highlighting efforts by the world's fourth largest drugmaker to penetrate the growing sector.
The group's Vitry-sur-Seine factory near Paris will be fully dedicated to researching, developing and producing biotechnology products and its doors will be thrown open to small biotech companies to help the French drugmaker discover new drugs.
"We will also welcome other biotechnology companies, we do this because collaborations can provide us with new products," chief executive Chris Viehbacher said on Tuesday.
"It's an opportunity for the company to do partnerships with biotechnology and research companies."
Sanofi aims to boost the number of its biotech-based products as they are harder to copy than chemical-based treatments.
"The investment of nearly 200 million euros will give rise to the first cell culture biotechnology platform of the group to produce monoclonal antibodies as from 2012," Sanofi said.
Monoclonal antibodies -- a fast-growing category of medicines used to treat diseases including cancer and rheumatoid arthritis -- are complex proteins that offer new possibilities for more effective treatments with fewer side effects.
Sanofi last week showed a refurbished pipeline of drugs in development, ditching 14, to focus on those with the most promising future as patent expiries on several key drugs opens the door to cheaper copies, threatening about a fifth of its sales.
At a conference call last week R&D head Marc Cluzel said Sanofi was a bit thin on drugs in early and mid-stage clinical trials. Accelerating partnership agreements with biotechnology companies could help fill in some of the gaps, he said.
Sanofi's slimmer portfolio now has 51 projects in clinical development of which 21 are in Phase III or have been submitted for regulatory approval.
Vaccines represent 35 percent of the total, other biological products 14 percent and external collaborations 27 percent.
Sanofi is also looking for bolt-on acquisitions to improve its pipeline.
Its name has been linked to many unconfirmed deals -- the possible takeover of the drug unit of Solvay in Belgium, U.S. biotech Biogen Idec, Dutch vaccine maker Crucell and India's Piramal Healthcare, Shantha Biotech, which is majority-owned by the French Merieux family, as well as a stake in Wockhardt's biotech business.
Viehbacher has said he is aiming to grow Sanofi through biotechnology partnerships and takeovers worth up to 15 billion euros in over-the-counter drugs, biotech, vaccines and generics, as well as expanding in fast-growing emerging markets.
Separately on Tuesday, IFR reported that Sanofi-Aventis was expected to sell 1.5 billion euros each of four-year and seven-year maturity bonds for a total of 3 billion euros of a dual-tranche bond. (Reporting by Caroline Jacobs, Editing by Tim Hepher and Dan Lalor)

www.guardian.co.uk/business/feedartic...
aossa
0
en.sanofi-aventis.com/binaries/200905...

Sanofi-aventis converts its Vitry-sur-Seine Industrial Facility to Biotechnologies

- The Biotechnology platform will regroup research, development and production activities -

Paris, France - May 5, 2009 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) officially launched today the BIOLAUNCH project at its Vitry-sur-Seine (France) pharmaceuticals production site, in the presence of Luc Chatel, Secretary of State for Industry and Consumption at the Ministry for the
Economy, Industry and Employment, Spokesman for the Government, Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis, Philippe Luscan, Senior-Vice President, Industrial Affairs, sanofi-aventis and Christian Lajoux, Chief Executive Officer of sanofi-aventis France.
BIOLAUNCH is a major operation for sanofi-aventis in France. The investment of nearly 200 million euros will give rise to the first cell culture biotechnoloy platform of the Group to produce monoclonal
antibodies as from 2012.

“With BIOLAUNCH, sanofi-aventis will benefit from a complete platform of expertise in biotechnologies. Monoclonal antibodies will open the way to a new generation of better targeted and more effective treatments with fewer side effects”, declared Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis. “This project, which gathers and mobilizes the best
expertise both inside and outside the company, is an illustration of the ongoing transforming program within sanofi-aventis”.

The BIOLAUNCH project is part of a long term approach to develop sanofi-aventis investments in the biotechnological sector, in continuity with the Group’s current activities in this area: production of vaccines, insulins and heparins.

This project is a core part of the conversion plan for the Vitry-sur-Seine site turning it into a comprehensive biotechnology platform that includes research, development and production activities.

Furthermore, sanofi-aventis has decided to open this platform to other companies, on the basis of their development or production needs.
The BIOLAUNCH project is joined with a major training program in new biotech business activities.

The program began in April 2009 and comprises special modules for both theory and practice, with a “BIOLAUNCH passport” syllabus.
Furthermore, this conversion is part of the sustainable development approach and environmental impact control program for this urban location. The site is currently classified as SEVESO II. This classification will end when the current chemicals activities will be transferred at the end of 2011.

About monoclonal antibodies
Monoclonal antibodies are complex proteins that come from a single parent cell and offer therapists new possibilities for better targeted and more effective treatments with fewer side effects. Today, they are already used in medical applications to treat cancer, autoimmune disorders, and prevent
transplant rejection.

About sanofi-aventis
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
aossa
0
Re: BIOLAUNCH

De vragen die me bezig houden:
* "Welke cellenlijn gaan ze installeren" ?
* "Wordt het een soort PERCIVIA, french pré-fried bistro of à la carte" ?
* "Verklaart dat het lange stilzwijgen vanwege Crucell" ?
maxen
1
quote:

aossa schreef:


Re: uitspraak Viehbacher betreffende cellen:
...
Derhalve kan Viehbacher in het openbaar stellen dat
Sanofi-Aventis proefondervindelijk heeft vastgesteld dat massaal produceren van flu-vaccine op cellenlijnen nog niet voor morgen is. Bedoelt dan de concurrentie imo ...


Ik weet niet precies wat ik van de recente Viehbacher uitspraken moet denken. WEL denk ik helaas dat Viehbacher op Sanofi ZELF doelt met uitspraak dat produceren van flu vaccine op cellijnen nog niet voor morgen is. Niet voor de concurrentie, want die produceert NU al deels op cellijnen.

Ik krijg al jaren de indruk dat Sanofi geen echte haast heeft met Per.C6, en dat dat een commerciele reden heeft: Productie op eitjes is nog zeer lonend, en Sanofi is hier marktleider in, en de fabrieken zijn nog lang niet afgeschreven. Kostenplaatje dus. Ze zijn ook niet bang om een paar jaar achter te lopen op de concurrentie, ze verwachten voorlopig niet op prijsniveau of kwaliteitsniveau weggeconcurreerd te worden.
In het geval dat blijkt dat in de markt toch de cellijn-vaccins sterk opkomen, schakelen ze alsnog een Per.C6 tandje bij.

Mijn VERMOEDEN (want meer is het niet) is dus dat Sanofi FluCell meer als een concurrent ziet dan als een opvolger van zijn huidige ei-vaccins.
Dat door een trage invoering van FluCell (want die volledige vervanging van eitjes naar cellen komt er natuurlijk ooit wel) de koers van Crucell ook nog wat achterblijft zou voordelig kunnen zijn bij een eventuele overname door Sanofi, is natuurlijk wel zo, maar lijkt mij in deze bijzaak.
aossa
0
Sanofi seeks collaborators for €200m biotech plant
By Gareth Macdonald, 05-May-2009
Related topics: Processing (automation, control, separation)

French drug major Sanofi Aventis has unveiled plans for a €200m ($268m) biotechnology investment at its manufacturing facility in Vitry-sur-Seine near Paris, under its collaborative Biolanuch project.

The investment will be used to install biotechnology manufacturing capacity at the plant which at present is used to produce Sanofi’s oncology, cardiovascular, anti-infectives and anti-inflammatories some of which are due to go off-patent in the next few years.

The core focus of the Biolaunch project is to develop a cell culture platform, R&D and manufacturing centre which, when fully operational in 2012, Sanofi will use to develop and manufacture monoclonal antibodies (MAbs) and biologics.

Sanofi CEO Christopher Viebacher said the project will create “a complete platform of expertise in biotechnologies,” adding that “monoclonal antibodies will open the way to a new generation of better targeted and more effective treatments with fewer side effects.”

He added that Biolanuch is “an opportunity for the company to do partnerships with biotechnology and research companies," explaining that such “collaborations can provide us with new products."

Sanofi’s focus on partnerships to bolster its pipelines, exemplified by its recent deal with Oxford Biomedica on eye disease, is not unusual among Big Pharma firms desperate to both cut costs and boost flagging pipelines.

Biolanuch will also include a training program to help with new biotech business activities that comprises special modules for both theory and practice, with participants gaining a “Biolanuch passport” syllabus.

Replenish product pipelines with biotech drugs

Last week, Viebacher announced a major reorganisation of the firm’s development pipeline that saw it cull 14 candidate drugs, including four that were in Phase III clinical trials.

At the time he said that said that Sanofi will shift its focus away from traditional drugs and “aim to increase the percentage of biotech products in its pipeline from 14 to 25 per cent over the next three years.”

Prior to that Sanofi demonstrated its commitment to expanding its biotechnology portfolio through the acquisition of Califorina, US based cancer drug specialist BiPar for $500m.

www.in-pharmatechnologist.com/content...
maxen
0
quote:

aossa schreef:


Re: BIOLAUNCH

De vragen die me bezig houden:
* "Welke cellenlijn gaan ze installeren" ?
* "Wordt het een soort PERCIVIA, french pré-fried bistro of à la carte" ?
* "Verklaart dat het lange stilzwijgen vanwege Crucell" ?

't Verklaart niets, maar geeft wel WEER een goede reden voor een overname: 27 gram/liter, enz.
Stopt weer net zoveel fantasie terug in het aandeel als er met de Viehbacher-trashtalk is uitgehaald.
[verwijderd]
0
aossa schreef:

Re: uitspraak Viehbacher betreffende cellen:

Uit het verleden weten we dat Aventis-pasteur verschillende cellenlijnen heeft getest en
1. Voor de menselijke cellijn PER.C6 heeft gekozen.
2. Alleen SA de PER.C6 mag gebruiken voor flu vaccine (cfr. exclusief contract).

Derhalve kan Viehbacher in het openbaar stellen dat
Sanofi-Aventis proefondervindelijk heeft vastgesteld dat massaal produceren van flu-vaccine op cellenlijnen nog niet voor morgen is. Bedoelt dan de concurrentie imo en heeft derhalve de tijd om rustig zijn cellen_flu_vaccine te ontwikkelen zonder grote concurrentiele druk.
Ook Vaxin, waarinCrucell een 5% belang heeft, ontwikkelt flu-vaccins m.b.v. Per.C6
Rockefeller
0
Sanofi-Aventis has successfully completed the placement of a 4-year and a 7-year Euro notes issue for an aggregate principal amount of EUR 3 billion

en.sanofi-aventis.com/binaries/200905...
ved
1
eitje erbij:

U.S. FDA Licenses Sanofi Pasteur's New Influenza Vaccine Manufacturing Facility
-- Sanofi Pasteur committed to increasing its seasonal and pandemic influenza preparedness; New facility will increase production capacity in the U.S. -

Last update: 6:06 p.m. EDT May 6, 2009
SWIFTWATER, Pa. and LYON, France, May 6, 2009 /PRNewswire-FirstCall via COMTEX/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration (FDA) has licensed its new influenza vaccine manufacturing facility.
This new facility, located in Swiftwater, Pennsylvania, will incorporate the latest technology in egg-based vaccine production as part of the company's commitment to produce the largest number of doses of vaccine in the shortest time frame to address the threat of seasonal and pandemic influenza.
The licensure of this facility today is for production of the company's seasonal trivalent influenza vaccine, Fluzone(R), Influenza Virus Vaccine, and augments the current Fluzone vaccine production capacity in the U.S. Sanofi Pasteur invested in the construction of this new $150 million, 140,000 square-foot (13,000 square-meter) vaccine facility as part of its commitment to support public health and to protect individuals against both seasonal and pandemic influenza. The new facility will produce 100 million doses when operating at full capacity.
In total, Sanofi Pasteur will have a capacity of approximately 150 million doses of trivalent seasonal influenza vaccine per year in the U.S. - 50 million doses from the existing facility and 100 million doses from the new facility when it is operating at full capacity. Production of Fluzone vaccine for the 2009-2010 season is already underway in the new facility.
"Sanofi Pasteur is assessing its capabilities to support public health efforts should the WHO and national health authorities request that influenza vaccine manufacturers start supplying vaccine to protect against the new influenza A (H1N1) virus," said Wayne Pisano, President and CEO of sanofi pasteur. "With the licensure of this new influenza vaccine production facility, Sanofi Pasteur now has additional flexibility to produce seasonal influenza vaccine and to respond to requests from public health authorities to develop an A (H1N1) vaccine."
As the world's leading influenza vaccine manufacturer, Sanofi Pasteur produces approximately 40 percent of the influenza vaccines distributed worldwide and in the U.S. produced more than 45 percent of the influenza vaccines distributed for the 2008-2009 influenza season.
About Influenza
Influenza is a highly-contagious respiratory illness with severe health implications that, at times, can lead to death. Influenza viruses spread in respiratory droplets caused by coughing and sneezing. They usually spread from person to person, though sometimes people become infected by touching something with influenza virus on it and then touching their eyes, nose or mouth. Globally, seasonal influenza causes between three and five million cases of severe illness and 250,000 to 500,000 deaths every year. In the U.S. on average each year, one out of five Americans suffers from seasonal influenza, approximately 226,000 are hospitalized, and 36,000 die from seasonal influenza and its complications. The best way to prevent influenza is to get an influenza vaccination.
In the U.S., the Centers for Disease Control and Prevention (CDC) recommends that health-care providers begin offering seasonal influenza vaccine as soon as vaccine becomes available in late August or September, and to continue immunization efforts throughout the season. Health-care providers are urged to continue immunization efforts until the end of influenza season. Approximately 250 million people, or four out of five residents of the U.S., are recommended to receive influenza vaccine annually. The CDC recommends an annual influenza immunization for anyone who wishes to reduce their risk of contracting influenza; children 6 months through 18 years of age; adults 50 years of age and older; pregnant women; and anyone with chronic health conditions, such as asthma, chronic obstructive pulmonary disease (COPD), heart disease, and diabetes. The CDC also recommends annual immunization for caregivers and household contacts of these high-risk groups; such as relatives and health-care providers.
At present there is not yet an influenza vaccine available to prevent influenza caused by the new influenza A (H1N1) virus. Sanofi Pasteur is working closely with the World Health Organization and the CDC to prepare for the development and production of a vaccine that would help prevent against this new influenza A (H1N1) virus. If public health authorities deem it necessary, due to worsening pandemic threat, Sanofi Pasteur is ready to produce a new influenza A (H1N1) vaccine candidate.
About Fluzone Vaccine
Fluzone vaccine is given to persons 6 months of age and older for active immunization against influenza virus types A and B contained in the vaccine. A Fluzone vaccine formulation (trade name: Fluzone, Influenza Virus Vaccine, No Preservative) that does not contain a preservative at any stage in the manufacturing process was introduced in 2004-2005. It is the first FDA-licensed injectable influenza vaccine to be manufactured in this way.
Important Information
Fluzone vaccine is given for active immunization in persons 6 months of age and older against influenza virus types A and B contained in the vaccine.
Side effects to Fluzone vaccine are soreness at the injection site that can last up to 2 days, pain, and swelling; fever, fatigue, and muscular pain. Other side effects may occur. Fluzone vaccine should not be administered to anyone with a history of serious allergic reaction to any vaccine component, including eggs, egg products, or thimerosal (the only Fluzone vaccine product containing thimerosal is the multi-dose vial), or to persons who have been previously diagnosed with Guillain-Barre syndrome (GBS). If you notice any other problems or symptoms following vaccination, please contact your health-care professional immediately. Vaccination with Fluzone vaccine may not protect all individuals.
For more information about Fluzone vaccine, talk to your health-care professional. The full Prescribing Information for Fluzone vaccine is available at www.Fluzone.com.

www.marketwatch.com/News/Story/Story....
maxen
0
quote:

ved schreef:


eitje erbij:
...
This new facility, located in Swiftwater, Pennsylvania, will incorporate the latest technology in egg-based vaccine production as part of the company's commitment to produce the largest number of doses of vaccine in the shortest time frame to address the threat of seasonal and pandemic influenza.
...


Splinternieuwe eitjesfabriek, nog lang niet afgeschreven.
Dirk R. Wijnen
0
HEARD ON THE STREET: Just Can't Get Enough

Last update: 5/7/2009 1:30:00 AM

(This story was originally published Wednesday.)

By Richard Barley
A DOW JONES COLUMN
Just four months of the year gone, and the European corporate bond market has already racked up its third-best year for issuance. This week, French pharmaceuticals group Sanofi-Aventis pulled in EUR22 billion of orders for a EUR3 billion bond in just 60 minutes. The explosion of activity in the bond markets is remarkable, but is it sustainable?

Perhaps. First, not all the demand is real. Some of the recent outsize orders - luxury goods maker LVMH, carmaker Volkswagen and utility Vattenfall have all seen deals covered many times over - simply reflect investors jockeying for position, inflating orders in the knowledge their allocations will be scaled back.

That said, every deal launched this year is trading at a tighter spread than when it was sold, according to Societe Generale. That suggests there is still plenty of demand even after launch. Second, demand is coming from a wide range of investors. Insurance companies and fund managers form the backbone, and there are increased allocations from pension funds, family offices and retail investors.

In short-dated maturities, non-traditional credit investors such as money-market funds are being enticed by the return pick-ups available over anemic government bond yields, bankers say. Third, while sales of non-financial bonds are rocketing, issuance of non-guaranteed financial bonds has fallen sharply, freeing up cash for industrials and the like.

Non-financial euro-denominated issuance may more than double from 2008 levels to a whopping EUR285 billion this year, according to Citigroup forecasts. But the drop off in financial bond sales means total credit issuance will rise just 2% to EUR507 billion.

But ultimately the bond market's record start to the year is being driven by the fallout from the crisis in the banking sector. Companies are bypassing banks and raising money direct from end investors - with both of them getting a better deal as a result. Disintermediation is the order of the day, and Europe's long-standing reliance on bank lending is in decline.

(Richard Barley is a writer for Heard on the Street. He has covered the European corporate credit market in one form or another since 1998. He can be reached at +44-20-7842-9406 or by email: richard.barley@dowjones.com)

TALK BACK: We invite readers to send us comments on this or other financial news topics. Please email us at TalkbackEurope@dowjones.com. Readers should include their full names, work or home addresses and telephone numbers for verification purposes. We reserve the right to edit and publish your comments along with your name; we reserve the right not to publish reader comments. (END)

Dow Jones NewswiresMay 07, 2009 01:30 ET (05:30 GMT)
flosz
0
Sanofi Pasteur's new facility in Swiftwater, Pennsylvania, is geared up to make vaccine using a conventional egg-based production technology, so would require four to six months to generate vaccine once the go-ahead has been given.

Cell culture-based production methods are faster but the company's efforts in this area have so far reached phase II clinical development and are still some way away from being a workable option.
Nevertheless, the new plant adds welcome production capacity as the scale of the swine flu outbreak remains under scrutiny, according to the FDA.

"Increased manufacturing capacity for influenza vaccine is critical to our preparedness for an influenza pandemic," said Dr Jesse Goodman, the FDA's acting chief scientist. Goodman is a recognised expert in influenza vaccines and is leading the agency's effort on the swine flu outbreak.
Sanofi Pasteur said it will have a capacity to make around 150 million doses of trivalent seasonal influenza vaccine a year for the US market, with 50 million doses coming from an older facility and 100 million doses from the new plant.
www.pharmafocus.com/cda/focusH/1,2109,21-0-0-MAY_2009-focus_news_detail-0-492755,00.html
msc
0
Flu vaccine may be shot in arm for drug industry
Mon May 11, 2009 12:26pm EDT

LONDON (Reuters) - For hard-pressed drugmakers, more used to attacks than applause, the H1N1 flu crisis is a chance to earn political capital by delivering billions of doses of vaccine across the planet.

Recent investment has put companies in far better shape to meet the challenge compared to five years ago, when a single factory closure in northwest England left the world worryingly short of seasonal flu shots.

This time around big flu vaccine makers like Sanofi-Aventis, GlaxoSmithKline and Novartis look set to book extra sales, although constraints on both capacity and pricing will cap the financial upside.

Until now, the main investor focus has been on stockpiling of antiviral drugs to fight the new strain of H1N1 flu, with Roche and Glaxo -- makers of Tamiflu and Relenza respectively -- the two obvious winners.

But that could be about to change as World Health Organization experts meet on May 14 to consider a switch from seasonal to pandemic vaccine production, with companies under intense pressure to show they are good citizens.

"It's not really about earnings accretion in 2009, it's about political goodwill with governments across the world for addressing one of the most acute public health concerns in recent history," said UBS pharmaceuticals analyst Gbola Amusa.

"That political goodwill is exceptionally valuable for these pharma companies."

In a highly regulated sector, where products are approved and bought in large part by governments, proving good citizenship is vital for securing decent prices for new medicines and winning concessions like tax breaks on R&D.

Company executives must tread a fine line by retaining business priorities while avoiding the kind of bad publicity that has surrounded costly AIDS drugs in developing countries.

msc
1
PRODUCTION FLEXIBILITY

Making a vaccine for the new strain, widely known as swine flu, will mean stopping most production of seasonal shots. But because some companies are now well advanced in making next season's regular vaccine, there is some room to meet both needs.

Companies are not divulging their production schedules but officials at two manufacturers said they were hopeful they would be finished with much of the production needed for the next northern hemisphere flu season by the time of any switch.

"There is some spare capacity and because seasonal flu is not manufactured all year round, there is some flex within the system," one said.

Marie-Paule Kieny, WHO director for vaccine research, told reporters last week a key factor in determining a switch would be an assessment of how much seasonal vaccine has already been made. She hopes the answer will be "lots."

783 Posts, Pagina: « 1 2 3 4 5 6 ... 12 13 14 15 16 17 18 19 20 21 22 ... 36 37 38 39 40 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Plaats een reactie

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 1 jan 0001 00:00
Koers 0,000
Verschil 0,000 (0,00%)
Hoog 0,000
Laag 0,000
Volume 0
Volume gemiddeld 0
Volume gisteren 0